No medicine may be lawfully marketed in the European Union without marketing authorisation. For Advanced Therapy Medicinal Products (ATMPs), the standard marketing authorisation pathway is the approval process called ‘centralised procedure’.
However, three additional legal procedures also exist to accelerate access to the market for products subject to centralised authorisation, as well as regulatory programmes established by the European Medicines Agency (EMA) in order to expedite access to medicines in Europe by assisting with the research and development processes.
